TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9989555

Group type: EXPERIMENTAL
Intervention: Nortriptyline plus interpersonal psychotherapy (N = 16)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nortriptyline alone in a medication clinic (N = 25)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo plus interpersonal psychotherapy (N = 17)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo alone in a medication clinic (N = 22)
Number of subjects: 80
Study: 8578012

Group type: EXPERIMENTAL
Intervention: External resistive loads (15 mm, 10 mm, 8 mm, 6 mm orifices)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: External resistive loads (10 mm and 8 mm orifices) during steady-state bicycle exercise
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: External resistive loads (6 mm orifice)
Number of subjects: 14
Study: 2180462

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cephamandole
Number of subjects: 120
Study: 7373080

Group type: COMPARATOR
Intervention: Inactivated B/Hong Kong virus vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Febrile respiratory illness monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influenza B virus infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemagglutination‐inhibiting antibody response
Number of subjects: 0
Study: 31754078

Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization with movement (MWM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham application
Number of subjects: 40
Study: 29910047

Group type: EXPERIMENTAL
Intervention: Udenafil, a phosphodiesterase type 5 inhibitor, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27351159

Group type: EXPERIMENTAL
Intervention: Intraoperative nerve root monitoring using the INS‐1‐System (NuVasive, San Diego USA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (screws inserted without additional pedicle monitoring)
Number of subjects: 22
Study: 22465123

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study: 22449253

Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 39
Study: 20718169

Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning (n=51)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physician-directed weaning (n=49)
Number of subjects: 100
Study: 17921381

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin A administered with BCG vaccine at birth
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 614
Study: 16140232

Group type: EXPERIMENTAL
Intervention: Severity of airflow obstruction (assessed by FEV(1)% predicted)
Number of subjects: 2116

Group type: EXPERIMENTAL
Intervention: Prior hospitalisation and home oxygen use
Number of subjects: 2116

Group type: EXPERIMENTAL
Intervention: Presence of comorbid conditions and symptoms of dyspnoea
Number of subjects: 2116
Study: 12401247

Group type: EXPERIMENTAL
Intervention: Ban on coal sales (intervention)
Number of subjects: 0
Study: 10327697

Group type: EXPERIMENTAL
Intervention: Burch technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colposuspension and support techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sling techniques
Number of subjects: 0
Study: 8712116

Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg/kg intravenously in 2 minutes)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Procainamide (10 mg/kg intravenously at an injection speed of 100 mg/min)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 29
Study: 1876376

Group type: EXPERIMENTAL
Intervention: Absorbable staples
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 60
Study: 6626854

Group type: EXPERIMENTAL
Intervention: Faded phobic cine-film exposure
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Supraliminal phobic cine-film exposure
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Subliminal phobic cine-film exposure
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (potter working on wheel)
Number of subjects: 32
Study: 31847979

Group type: EXPERIMENTAL
Intervention: Blended education program for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional face-to-face education (Control)
Number of subjects: 60
Study: 28403569

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 26415612

Group type: EXPERIMENTAL
Intervention: Visual neurofeedback training (12 sessions over 6 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No additional NF intervention (control group)
Number of subjects: 25
Study: 25790416

Group type: EXPERIMENTAL
Intervention: Worksite multiple-component intervention addressing diet and physical activity
Number of subjects: 3799

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3799

Group type: EXPERIMENTAL
Intervention: Difference in differences (DID)
Number of subjects: 3799
Study: 22502833

Group type: EXPERIMENTAL
Intervention: home-based virtual cycling training (hVCT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: control group
Number of subjects: 28
Study: 20428608

Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate (160 mg) with alcohol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate (160 mg) alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 18803991

Group type: EXPERIMENTAL
Intervention: SFC 50/100 microg BID
Number of subjects: 548

Group type: COMPARATOR
Intervention: MON 5-mg tablet QD
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: SFC
Number of subjects: 548

Group type: COMPARATOR
Intervention: MON
Number of subjects: 548
Study: 16061734

Group type: EXPERIMENTAL
Intervention: CONJ‐hBNP
Number of subjects: 0

Group type: COMPARATOR
Intervention: native hBNP
Number of subjects: 0
Study: 11799078

Group type: EXPERIMENTAL
Intervention: L-arginine infusion (1 g/min; total 30 g)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hydralazine infusion (control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: D-arginine infusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 11
Study: 10818895

Group type: EXPERIMENTAL
Intervention: Adhesive hydro‐cellular dressing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paraffin gauze dressing
Number of subjects: 50
Study: 8750409

Group type: EXPERIMENTAL
Intervention: Three alternative models of patient counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1827283

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 80
Study: 6662724

Group type: EXPERIMENTAL
Intervention: High initial dosage of oral aromatic retinoid (75 mg leads to 50 leads to 35 mg; approximately 1 mg/kg/d leads to approximately 0.5 mg/kg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low initial dosage of oral aromatic retinoid (35 mg leads to 50 mg/d leads to 75 mg/d; approximately 0.5 mg/kg/d leads to approximately 1.0 mg/kg/d)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Moderate doses of oral aromatic retinoid (35-60 mg/d; approximately 0.4-0.8 mg/kg/d)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High initial dosage of retinoid
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Classical side effects (cheilitis, desquamation, hair loss)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Elevations of serum triglycerides
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hair loss in females
Number of subjects: 70
Study: 30539282

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy combined with intravesical chemotherapy (Group A, n=68)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Intravesical chemotherapy alone (Group B, n=135)
Number of subjects: 203
Study: 28122931

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D supplements every 2 weeks for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo every 2 weeks for 6 months
Number of subjects: 60
Study: 25689146

Group type: EXPERIMENTAL
Intervention: AFQ056 (25-150 mg, twice-daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 25022106

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with auricular point sticking
Number of subjects: 90

Group type: COMPARATOR
Intervention: Body acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medication (aniracetam tablets, 0.2 g twice a day)
Number of subjects: 90
Study: 21986389

Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol), 2000 IU/day
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acid (Omacor fish oil, EPA+DHA), 1g/day
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20000
Study: 19487506

Group type: EXPERIMENTAL
Intervention: Surgical repair of medial collateral ligament (Group I, n = 23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Anterior cruciate ligament reconstruction only (Group II, n = 24)
Number of subjects: 47
Study: 17580264

Group type: EXPERIMENTAL
Intervention: (T)BU/CY
Number of subjects: 222

Group type: COMPARATOR
Intervention: CY/TBI
Number of subjects: 222
Study: 17893453

Group type: EXPERIMENTAL
Intervention: Profound hemodilution (hematocrit on cardiopulmonary bypass of 15‐18%)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Moderate hemodilution (hematocrit on cardiopulmonary bypass >or=27%)
Number of subjects: 108
Study: 15575569

Group type: EXPERIMENTAL
Intervention: Activated charcoal silver dressing
Number of subjects: 125

Group type: COMPARATOR
Intervention: Cleansing and debridement (control)
Number of subjects: 125
Study: 10856489

Group type: EXPERIMENTAL
Intervention: Lignocaine gel
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo (no anesthesia)
Number of subjects: 500
Study: 9188228

Group type: EXPERIMENTAL
Intervention: Evidence-based periodontal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical periodontal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dental implants
Number of subjects: 0
Study: 8252492

Group type: EXPERIMENTAL
Intervention: Goserelin and flutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 0
Study: 3548985

Group type: EXPERIMENTAL
Intervention: Diflunisal (500 to 750 mg daily, increased to a maximum of 1 gm daily during the open-label phase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (2.6 to 3.9 gm daily)
Number of subjects: 0
Study: 31265915

Group type: EXPERIMENTAL
Intervention: Wearable device or smartphone application to track physical activity data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard modelling approaches
Number of subjects: 0
Study: 28479526

Group type: EXPERIMENTAL
Intervention: Superion device
Number of subjects: 122
Study: 26264837

Group type: EXPERIMENTAL
Intervention: Vaporized nicotine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22617142

Group type: EXPERIMENTAL
Intervention: Self-reported FFQ for EPA
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Self-reported FFQ for DHA
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Self-reported FFQ for sum of n-3 PUFA
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Erythrocyte levels of EPA
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ranked thirds of dietary intake, blood and dermis
Number of subjects: 78
Study: 21791491

Group type: COMPARATOR
Intervention: Angiotensin receptor blockade (valsartan 320 mg/day) plus regular sodium diet (200 mmol Na(+)/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockade (valsartan 320 mg/day) plus low sodium diet (50 mmol Na(+)/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: ACE inhibition (lisinopril 40 mg/day) plus regular sodium diet (200 mmol Na(+)/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ACE inhibition (lisinopril 40 mg/day) plus low sodium diet (50 mmol Na(+)/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ACE inhibition (lisinopril 40 mg/day) plus angiotensin receptor blockade (valsartan 320 mg/day)
Number of subjects: 52
Study: 19422751

Group type: EXPERIMENTAL
Intervention: Live modelling with mother as model
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Live modelling with father as model
Number of subjects: 155

Group type: COMPARATOR
Intervention: Tell-show-do method
Number of subjects: 155
Study: 16859866

Group type: EXPERIMENTAL
Intervention: Information brochure provided at least 1 day before the gastroscopy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no brochure)
Number of subjects: 95
Study: 15745073

Group type: EXPERIMENTAL
Intervention: Essay test format
Number of subjects: 67

Group type: COMPARATOR
Intervention: Fill-in test format
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both test formats
Number of subjects: 67
Study: 11552907

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 420 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ranitidine plus calcium carbonate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Antacid alone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ranitidine plus antacid
Number of subjects: 26
Study: 9758574

Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 409

Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 409
Study: 7818585

Group type: EXPERIMENTAL
Intervention: roxatidine (150 mg daily) with diclofenac (100 mg daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: diclofenac (100 mg daily) with placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: misoprostol (200 micrograms bid) with diclofenac (100 mg daily)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: diclofenac (100 mg daily) with roxatidine (150 mg daily)
Number of subjects: 44
Study: 3276865

Group type: EXPERIMENTAL
Intervention: Plasma infusion (P+ group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Symptomatic therapy (P- group)
Number of subjects: 32
Study: 31055011

Group type: EXPERIMENTAL
Intervention: Ads featuring Black actors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ads featuring White actors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ads featuring Blacks
Number of subjects: 0
Study: 28064525

Group type: EXPERIMENTAL
Intervention: Wellness Journey (healthy lifestyle intervention)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Safety Journey (child safety control group)
Number of subjects: 450
Study: 26047957

Group type: EXPERIMENTAL
Intervention: Resistance training program (12 weeks, 8 exercises, 2 sets, 10-15 repetitions, 3 days/week)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Stretching exercises (12 weeks, 2 sets, 20 s each, 2 days/week)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Resistance training program (after intervention)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Stretching exercises (after intervention)
Number of subjects: 28
Study: 24018103

Group type: EXPERIMENTAL
Intervention: SLC18A2 gene SNPs (specifically rs2015586 and rs363224)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Interaction of rs363224 with D2 receptor rs6277 (C957T) polymorphism
Number of subjects: 217
Study: 21262997

Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 119
Study: 18006647

Group type: EXPERIMENTAL
Intervention: 200 mg of [(14)C]dabigatran etexilate (oral prodrug)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5 mg of [(14)C]dabigatran (i.v. infusion)
Number of subjects: 10
Study: 16448817

Group type: EXPERIMENTAL
Intervention: MRI with a novel splint that stresses the knee
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 14
Study: 15043790

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 19287

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 19287
Study: 11118564

Group type: EXPERIMENTAL
Intervention: Sertaconazole 300 mg suppository
Number of subjects: 369

Group type: COMPARATOR
Intervention: Econazole 150 mg suppository
Number of subjects: 369
Study: 9345696

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcortical ischemic vascular dementia (IVD) participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8475322

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other hypnotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residual effects of hypnotics
Number of subjects: 0
Study: 2417648

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (US) at 1.5 W.cm-2
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (US) at 0.1 W.cm-2
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (US) at 0.5 W.cm-2
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Placebo group ('mock' US)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 150
Study: 29788802

Group type: EXPERIMENTAL
Intervention: Inhaled menthol (0.0%, 0.5%, and 3.2%)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Saline and nicotine infusions (0.25 mg and 0.5 mg/70 kg)
Number of subjects: 57
Study: 26858092

Group type: EXPERIMENTAL
Intervention: Forced-air convective warming at 46°C for one hour
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine care (full body blanket with convective warmer attached but not turned on)
Number of subjects: 32
Study: 25185255

Group type: EXPERIMENTAL
Intervention: INTRACOR procedure with six concentric intrastromal ring cuts
Number of subjects: 20
Study: 22954721

Group type: COMPARATOR
Intervention: Rotigotine transdermal system
Number of subjects: 0
Study: 20684440

Group type: EXPERIMENTAL
Intervention: Fluoride releasing materials (glass ionomers, resin modified glass ionomers, compomers)
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 1341
Study: 18208463

Group type: EXPERIMENTAL
Intervention: 0.1% methylprednisolone aceponate cream + emollients (Group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 0.1% methylprednisolone aceponate cream (Group A)
Number of subjects: 52
Study: 17010794

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration before PCI
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard PCI (Control)
Number of subjects: 50
Study: 14582594

Group type: EXPERIMENTAL
Intervention: Indirect resin composite inlays/onlays (Tetric, Z100, Maxxim)
Number of subjects: 25
Study: 10753981

Group type: EXPERIMENTAL
Intervention: Conventional-intensity warfarin therapy (INR 2.2 to 3.5)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Low-intensity warfarin therapy (INR 1.5 to 2.1)
Number of subjects: 115
Study: 9279294

Group type: EXPERIMENTAL
Intervention: Bambuterol 20 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 7512462

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3555359

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 50 mg intramuscularly every third week for two years
Number of subjects: 47

Group type: COMPARATOR
Intervention: No anabolic steroids (Control)
Number of subjects: 47
Study: 29922752

Group type: EXPERIMENTAL
Intervention: Dual‐cure self‐adhesive composite cement (Multilink Speed, Ivoclar Vivadent) light-cured for 20 s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dual‐cure self‐adhesive composite cement (Multilink Speed, Ivoclar Vivadent) light-cured for 40 s
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (20-degree and 30-degree zirconia surfaces)
Number of subjects: 40
Study: 28511500

Group type: EXPERIMENTAL
Intervention: HiOra mouthwash
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Probiotic mouthwash
Number of subjects: 45

Group type: COMPARATOR
Intervention: CHX mouthwash
Number of subjects: 45
Study: 25677642

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Insulin detemir plus sitagliptin
Number of subjects: 90
Study: 23545909

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% foaming cloth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tretinoin 0.025%/clindamycin phosphate 1.2% gel alone
Number of subjects: 0
Study: 20042524

Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 210
Study: 18405146

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 66

Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 66
Study: 16870083

Group type: EXPERIMENTAL
Intervention: Goshuyuto
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 12823170

Group type: EXPERIMENTAL
Intervention: Self-factor and two psychopathology factors as mediators of self-rated quality of life
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Trait-like properties such as the self-factor and personality
Number of subjects: 117
Study: 10629624

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg i.v. q 4 weeks
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 7560474

Group type: EXPERIMENTAL
Intervention: Noradrenaline (0.14 microgram/kg min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Adrenaline (0.08 microgram/kg min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dopamine (7 micrograms/kg min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9